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Abstract
Purpose Pazopanib plus gemcitabine combination ther-
apy was explored in patients with advanced solid tumors.
Methods In a modified 3 ? 3 enrollment scheme, oral
once-daily pazopanib was administered with intravenous
gemcitabine (Days 1 and 8, 21-day cycles). Three protocol-
specified dose levels were tested: pazopanib 400 mg plus
gemcitabine 1,000 mg/m2, pazopanib 800 mg plus gem-
citabine 1,000 mg/m2, and pazopanib 800 mg plus gem-
citabine 1,250 mg/m2. Maximum-tolerated dose was based
on dose-limiting toxicities during treatment Cycle 1. In the
expansion phase, six additional patients were enrolled at
the highest tolerable dose level.
Results Twenty-two patients were enrolled. At the high-
est dose level tested (pazopanib 800 plus gemcitabine
1,250), patients received [80 % of their planned dose and
the regimen was deemed safe and tolerable. The most
common treatment-related adverse events included fatigue,
neutropenia, nausea, and decreased appetite. Neutropenia
and thrombocytopenia were the most common events
leading to dose modifications. Pharmacokinetic interaction
between pazopanib and gemcitabine was not observed. One
objective partial response at the highest dose was observed
in a patient with metastatic melanoma. Prolonged disease
stabilization ([12 cycles) was reported in three patients
(metastatic melanoma, cholangiocarcinoma, and colorectal
carcinoma).
Conclusion Combination pazopanib plus gemcitabine
therapy is tolerable, with an adverse event profile reflective
of that associated with the individual agents. There was no
apparent pharmacokinetic interaction with pazopanib plus
gemcitabine co-administration, although patient numbers
were limited. Further investigation of combined pazopanib
plus gemcitabine is warranted.
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Introduction
Pazopanib is a multi-tyrosine kinase inhibitor of vascular
endothelial growth factor receptor (VEGFR)-1, VEGFR-2,
VEGFR-3, platelet-derived growth factor receptor
(PDGFR)-a, PDGFR-b, fibroblast growth factor receptor
(FGFR)-1, FGFR-3, and c-Kit. Pazopanib is approved as
monotherapy for patients with advanced renal cell carci-
noma [1] and soft tissue sarcoma [2] and is currently under
investigation in multiple tumor types, including ovarian
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cancer, non-small-cell lung cancer, thyroid cancer, and
cervical cancer [3–7].
Gemcitabine is a cytotoxic nucleoside analogue of
deoxycytidine whose triphosphate (dFdCTP) is irreversibly
incorporated into DNA, subsequently inhibiting exonucle-
ase and DNA repair activities. Gemcitabine has broad-
spectrum activity and is approved or commonly used,
either as a single agent or in combination with other che-
motherapy agents, for the treatment of ovarian cancer,
breast cancer, non-small-cell lung cancer, pancreatic can-
cer, and soft tissue sarcoma [8–12]. Myelosuppression was
the dose-limiting toxicity (DLT) in gemcitabine single-
agent Phase I trials [13, 14].
Clinical studies exploring therapeutic strategies that
combine angiogenesis pathway inhibition with concurrent
chemotherapy have shown promise for the treatment of
various malignancies [15–17]. Therefore, a Phase I study
(NCT00678977; VEG109599) was conducted to determine
the maximum-tolerated dose (MTD) of pazopanib in
combination with gemcitabine. Secondary objectives
included evaluation of safety and pharmacokinetics of the
combination and assessment of the preliminary clinical
activity in patients with advanced solid tumors.
Patients and methods
Study participants
Eligible patients were at least 18 years of age with a his-
tologically or cytologically confirmed advanced solid
tumor, who had progressed on standard therapy or for
whom no standard therapy was available. Additional eli-
gibility criteria included an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1; measurable or
evaluable disease at the time of screening; adequate
hematologic, hepatic, and renal function; and no unstable
or serious concurrent medical condition. An unlimited
number of prior therapies were permitted; however, at least
4 weeks must have elapsed since previous treatment.
Patients with asymptomatic brain metastases who did not
require steroids and antiseizure medications for more than
3 months were eligible.
Exclusion criteria included the presence of leptomenin-
geal carcinomatosis; clinically significant gastrointestinal
abnormality; elevated blood pressure (C140/90 mmHg);
prolonged QT interval ([480 ms); history of cardiac
angioplasty or stenting, myocardial infarction, unstable
angina, symptomatic peripheral vascular disease, or Class
III or IV congestive heart failure; uncontrolled infection;
history of cerebrovascular accident, pulmonary embolism,
or untreated deep vein thrombosis within the previous
6 months; and previous treatment with an investigational
or licensed tyrosine kinase inhibitor targeting VEGF
receptors.
The study was conducted in accordance with the stan-
dards of each site’s independent ethics committees, prin-
ciples of good clinical practice, all applicable regulatory
requirements, and the Declaration of Helsinki. All patients
provided written informed consent before enrollment and
before undergoing any study-specific procedures.
Study design
This open-label study consisted of a dose-escalation phase
to determine the MTD and a fixed-dose, cohort-expansion
phase to further define the safety and tolerability of the
MTD. The dose-escalation phase used a 3 ? 3 enrollment
design. Initially, three patients were enrolled into Dose
Level 1; if no DLT was observed, three patients were
enrolled at the next dose level. If a DLT was observed in
one of the first three patients enrolled at a given dose level,
three additional patients were enrolled at that dose level.
Escalation to the subsequent dose level was permitted if no
more than one of six patients experienced a DLT. If,
however, two or more patients experienced a DLT at a
given dose level, the MTD was considered to have been
exceeded and a lower or intermediate dose level would be
explored.
Dose-limiting toxicity was based on observed toxicity
during the first cycle of treatment. Toxicities included the
following: Grade 4 neutropenia, febrile neutropenia, Grade
4 anemia, platelet count below 25,000, serum creatinine at
least 2 times baseline or upper limit of normal, Grade 3
proteinuria with uncontrolled hypertension or renal
impairment and Grade 4 proteinuria, Grade 3 or higher
non-hematologic toxicity (except fatigue but including
nausea, vomiting, and diarrhea not controlled by supportive
treatment), Grade 3 uncontrolled hypertension, Grade 4
hypertension, delay of treatment for more than 3 weeks, or
inability to receive 75 % of scheduled doses in a treatment
cycle.
Treatment
During the dose-escalation phase, 3 protocol-defined dose
regimens were evaluated. In this phase, pazopanib was
administered orally once daily beginning on Day 1 of
Cycle 1, and gemcitabine was administered intravenously
on Day 1 and Day 8 of each 21-day cycle. In the cohort-
expansion phase, gemcitabine was administered on the
same schedule, but daily pazopanib dosing began on Day 2
of Cycle 1 to permit determination of gemcitabine-alone
pharmacokinetics on Day 1. Gemcitabine infusions were
administered over 30 min. Intrapatient dose escalations
were not permitted. Dose modifications and reductions for
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pazopanib were to be performed for the control of blood
pressure or in the event of hemorrhage, thrombosis,
proteinuria, or hepatotoxicity. Dose modifications and
reductions for gemcitabine were based on hematologic
toxicity and other toxicities causally related to gemcita-
bine. Treatment could continue in the absence of unac-
ceptable toxicities, disease progression, patient withdrawal
of consent, investigator decision, or a delay in treatment for
more than 3 weeks.
Patient evaluation
Screening assessments were completed within 28 days
before the first dose of study treatment; these included
medical history, prior anticancer therapy, physical exami-
nation, ECOG performance status, vital signs, hematology,
and clinical chemistry. Baseline electrocardiogram and
echocardiogram or multi-gated acquisition (MUGA) scans
were also performed.
Safety was assessed throughout the study by physical
examination, 12-lead electrocardiograms, echocardiograms
or MUGA, vital sign measurements, and clinical laboratory
tests. Patients were monitored for adverse events (AEs)
throughout the study. The frequency, severity, and rela-
tionship to treatment for AEs that occurred during study
treatment and up to 30 days after the last dose of study
drug were evaluated. Adverse events were coded according
to the Medical Dictionary for Regulatory Activities
(MedDRA) and Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. All patients who
received at least one dose of study drug were included in
the safety analyses.
Disease assessment was performed within 28 days
before the first dose of study treatment and every 2 treat-
ment cycles thereafter. All patients completing at least 2
treatment cycles were evaluable for response. Tumor
response was evaluated according to Response Evaluation
Criteria in Solid Tumors [18]. Confirmatory scans were
required at least 4 weeks after the initial documentation of
a complete or partial response.
Pharmacokinetic sampling
Sparse sampling was performed during the dose-escalation
phase; serial blood samples for plasma pazopanib analysis
were nominally collected pre-dose and 3.5 h post-dose on
Day 1 of Cycle 1, and pre-dose on Day 8 of Cycle 1 and
Day 1 of Cycle 2. Blood samples for analysis of plasma
gemcitabine and its metabolite, 20,20-difluorodeoxyuridine
(dFdU), were nominally collected pre-dose and at 0.5 h
(i.e., at the end of gemcitabine infusion) on Days 1 and 8 of
Cycle 1. In the cohort-expansion phase, blood samples
for plasma gemcitabine and dFdU analysis were collected
pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 h after
the start of the gemcitabine infusion on Day 1 of Cycle 1
(gemcitabine alone) and at the same times on Day 1 of
Cycle 2 (gemcitabine and pazopanib in combination) for
gemcitabine, dFdU, and pazopanib analysis.
Drug concentration assays
Plasma samples were analyzed for pazopanib using a val-
idated analytical method based on protein precipitation,
followed by high-performance liquid chromatography/tan-
dem mass spectrometry (HPLC/MS/MS) analysis [19]. The
lower limit of quantification (LLQ) was 100 ng/mL, using
a 20-lL aliquot of human plasma with a higher limit of
quantification (HLQ) of 50,000 ng/mL. Plasma concen-
trations of gemcitabine and dFdU were determined using a
validated method based on liquid/liquid extraction with
methyl tertiary-butyl ether (MTBE) and chemical deriva-
tization with dansyl chloride, followed by HPLC/MS/MS
analysis. The LLQ for gemcitabine and dFdU was 50 and
500 ng/mL, respectively, using a 50-lL aliquot of human
plasma with HLQ of 50,000 ng/mL for both gemcitabine
and dFdU. For each assay, quality control (QC) samples,
prepared at three different analyte concentrations and
stored with study samples, were analyzed with each batch
of samples against separately prepared calibration stan-
dards. For the analysis to be acceptable, no more than one-
third of the QC results were to deviate from the nominal
concentration by more than 15 %, and at least 50 % of the
results from each QC concentration would be within 15 %
of nominal.
Statistical and pharmacokinetic analysis
Statistical analyses were performed using the SAS/STAT
module of SAS, version 9 (SAS Institute, Cary, NC). Phar-
macokinetic concentrations (dose-escalation and expansion
cohorts) and pharmacokinetic parameters (expansion cohort
only) for pazopanib, gemcitabine, and dFdU were summa-
rized by dose cohort. In the expansion cohort, for each of the
analytes, pharmacokinetic parameter estimates were obtained
for maximum concentration (Cmax), time of Cmax, area under
the plasma concentration–time curve (AUC) from time 0 to
time post-dose of last quantifiable concentration, and elimi-
nation half-life. For gemcitabine, AUC extrapolated to
infinity (AUC(0–?)) and systemic clearance were estimated;
AUC(0–?) was also estimated for dFdU. To assess the
potential effect of pazopanib on gemcitabine pharmacoki-
netics, gemcitabine and dFdU pharmacokinetic parameters
Cmax, AUC(0–?), and elimination half-life were loge-trans-
formed and analyzed by mixed-effect analysis of variance
(ANOVA), fitting terms for treatment (test: pazopanib plus
gemcitabine [Cycle 2, Day 1]; reference: gemcitabine alone
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[Cycle 1, Day 1]) as a fixed effect and patient as a random
effect. Geometric least squares means and 90 % confidence
intervals (CI) for the differences in loge-transformed param-
eters were then back-transformed to obtain the geometric
mean ratio (test/reference) and associated 90 % CI on the
original scale.
Adverse events were listed and summarized by treat-
ment regimen and the percent of patients reporting each
event at least once. Laboratory parameters, vital signs, and
electrocardiograms were summarized by time point and
treatment regimen. Dose intensity was defined as ([actual
dose/planned dose] 9 100).
Results
Patient characteristics
Between April 2008 and March 2010, a total of 22 patients
with advanced solid tumors were enrolled and treated with
pazopanib plus gemcitabine; 21 patients completed the
study. Two patients with melanoma who received pazop-
anib 800 mg plus gemcitabine 1,250 mg/m2 (Paz800/
Gem1250) continued pazopanib treatment for an additional
14 and 16 months, respectively, after database lock. The
most frequent tumor type was melanoma (eight patients,
36 %; Table 1). All patients had received at least 1 prior
line of chemotherapy; 13 patients (59 %) had received at
least 2 prior lines of chemotherapy.
Dose escalation and determination of MTD
A DLT of Grade 4 thrombocytopenia was reported in one
of the initial three patients (Table 2) enrolled in Dose Level
1 (pazopanib 400 mg plus gemcitabine 1,000 mg/m2
[Paz400/Gem1000]). As a result, Dose Level 1 was
expanded to a total of six patients. No further DLTs were
reported in Dose Level 1. No DLTs were observed in the
dose-escalation phase of Dose Level 2 (pazopanib 800 mg
plus gemcitabine 1,000 mg/m2 [Paz800/Gem1000]) or in
the first three patients enrolled in Dose Level 3 (Paz800/
Gem1250). Because Dose Level 3 was the highest protocol-
defined dose level at which pazopanib and gemcitabine were
administered at therapeutic levels equivalent to that of
monotherapy with the individual agents, additional dose
levels were not evaluated. Thus, the MTD was not deter-
mined. Overall, 1 DLT (Grade 3 fatigue) was reported
among 13 patients enrolled in Dose Level 3 in the dose-
escalation and cohort-expansion phase.
Table 1 Patient demographics and disease characteristics at baseline
Paz400/Gem1000 (n = 6) Paz800/Gem1000 (n = 3) Paz800/Gem1250 (n = 13) Total (N = 22)
Gender (n %)
Female 4 (67) 2 (67) 5 (38) 11 (50)
Male 2 (33) 1 (33) 8 (62) 11 (50)
Race (n %)
White 6 (100) 3 (100) 13 (100) 22 (100)
Ethnicity (n %)
Hispanic or Latino 0 0 0 0
Not Hispanic or Latino 6 (100) 3 (100) 13 (100) 22 (100)
Median age, years (range) 56 (22–63) 49 (47–52) 63 (30–74) 56 (22–74)
ECOG PS (n %)
0 2 (33) 3 (100) 9 (69) 14 (64)
1 4 (67) 0 4 (31) 8 (36)
Primary tumor (n %)
Melanoma 1 (17) 1 (33) 6 (46) 8 (36)
NSCLC 0 0 3 (23) 3 (14)
Colorectal 1 (17) 1 (33) 1 (8) 3 (14)
Cervix 1 (17) 0 0 1 (5)
Esophagus 0 0 1 (8) 1 (5)
Ovarian 1 (17) 0 0 1 (5)
Stomach 0 0 1 (8) 1 (5)
Other 2 (33) 0 1 (8) 3 (14)
Unknown 0 1 (33) 0 1 (5)
ECOG PS Eastern Cooperative Oncology Group performance status, Gem gemcitabine, NSCLC non-small-cell lung cancer, Paz pazopanib
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Exposure
The median number of cycles of pazopanib and gemcitabine
received in the Paz400/Gem1000 (n = 6), Paz800/
Gem1000 (n = 3), and Paz800/Gem1250 (n = 13) dose
levels were 5.5 cycles (range 2–17), 6 cycles (range 5–12),
and 4 cycles (range 1–14), respectively. The median dose
intensity for each of the three dose levels tested was as
follows: Paz400/Gem1000, 99 %/78 %; Paz800/Gem1000,
95 %/78 %; and Paz800/Gem1250, 100 %/81 %. At least
one pazopanib dose delay was observed in 12 patients
(55 %), and 17 patients (77 %) had at least one gemcitabine
dose delay. Across all dose levels, the most common AEs
leading to a dose delay were neutropenia (three patients,
14 %), thrombocytopenia (2 patients, 9 %), and diarrhea
(two patients, 9 %). Two patients (9 %) required at least
one pazopanib dose reduction, whereas 12 patients (55 %)
required at least one gemcitabine dose reduction. The most
common AEs resulting in dose reductions were neutropenia
(41 %), thrombocytopenia (14 %), and hypertension (5 %).
Safety and tolerability
The most common treatment-related AEs reported in
patients across all dose levels were fatigue (68 %), neu-
tropenia (59 %), nausea (55 %), and decreased appetite
(50 %; Table 3). The majority of treatment-related AEs
were Grade 1 or 2. Seven patients (32 %) across all dose
levels experienced Grade 4 treatment-related AEs of neu-
tropenia and thrombocytopenia. The majority of patients
(41 %) discontinued treatment due to disease progression;
three patients (14 %) discontinued due to AEs (Grade 3
increased alanine aminotransferase, Grade 1 hematoma,
and Grade 3 fatigue), two patients (9 %) discontinued at
the investigator’s discretion, and four patients (18 %)
withdrew consent. One treatment-related death (Grade 5
pneumonia) was reported in Dose Level 1 (Paz400/
Gem1000).
Pharmacokinetics
There was considerable variability in plasma concentra-
tions of pazopanib, gemcitabine, and dFdU during the
sparse sampling for patients in the dose-escalation phase
(Table 4). Given this variability and the relatively small
number of patients enrolled in each cohort, dose








Paz400/Gem1000 6 1b 5.5 (2–17) 5.5 (2–17)
Paz800/Gem1000 3 0 6 (5–12) 6 (5–12)
Paz800/Gem1250 13 1c 4 (1–14) 4 (1–14)
DLT dose-limiting toxicity, Gem gemcitabine, Paz pazopanib
a Observed during Cycles 1 and 2 during the dose-escalation phase
b Grade 4 thrombocytopenia
c Grade 3 fatigue
Table 3 Treatment-related adverse events occurring in C10 % of overall patient population
Adverse event (n %) Paz400/Gem1000 (n = 6) Paz800/Gem1000 (n = 3) Paz800/Gem1250 (n = 13) Total (N = 22)
Fatigue 4 (67) 3 (100) 8 (62) 15 (68)
Neutropenia 4 (67) 1 (33) 8 (62) 13 (59)
Nausea 4 (67) 2 (67) 6 (46) 12 (55)
Decreased appetite 2 (33) 1 (33) 8 (62) 11 (50)
Leukopenia 2 (33) 1 (33) 7 (54) 10 (45)
Thrombocytopenia 3 (50) 1 (33) 5 (38) 9 (41)
Diarrhea 3 (50) 1 (33) 4 (31) 8 (36)
Vomiting 1 (17) 1 (33) 4 (31) 6 (27)
ALT increased 1 (17) 2 (67) 3 (23) 6 (27)
Dysgeusia 2 (33) 3 (100) 1 (8) 6 (27)
Stomatitis 4 (67) 1 (33) 0 5 (23)
Alopecia 0 0 4 (31) 4 (18)
Hair color changes 1 (17) 0 3 (23) 4 (18)
AST increased 1 (17) 1 (33) 2 (15) 4 (18)
Epistaxis 0 1 (33) 3 (23) 4 (18)
Dry skin 1 (17) 1 (33) 1 (8) 3 (14)
ALT alanine aminotransferase, AST aspartate aminotransferase, Gem gemcitabine, Paz pazopanib
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proportionality could not be reasonably assessed. In addi-
tion, elevations in plasma levels of pazopanib, gemcita-
bine, or dFdU were not associated with occurrence of either
of the 2 DLTs noted above (i.e., Grade 4 thrombocytopenia
reported on Cycle 1 Day 8 for one patient in the Paz400/
Gem1000 group and Grade 3 fatigue on Cycle 1 Day 1 for
one patient in the Paz800/Gem1250 cohort).
Six patients in the cohort-expansion phase had frequent
sampling performed for pharmacokinetic analysis. Median
concentration–time profiles for pazopanib (Cycle 2 Day 1)
and for gemcitabine and dFdU after dosing of gemcitabine
alone (Cycle 1 Day 1) and in combination with pazopanib
(Cycle 2 Day 1) are presented in Fig. 1. The median
gemcitabine and dFdU concentration profiles from gem-
citabine alone and from gemcitabine after 21 days of
pazopanib administration appear very similar. Gemcita-
bine is rapidly transformed into dFdU which quickly
achieves appreciably greater concentrations with a much
longer elimination half-life. Summary pharmacokinetic
parameters for pazopanib, gemcitabine, and dFdU are
presented in Table 5, along with statistical results from the
ANOVA investigating the effect of pazopanib on gemcit-
abine pharmacokinetics. Because of missed samples, not
all pharmacokinetic parameters could be estimated for all
patients. Results from the statistical analysis suggest that
gemcitabine and dFdU systemic exposures are slightly
higher with pazopanib co-administration, with Cmax and
AUC geometric least squares mean ratios of 1.06 (90 % CI:
0.62, 1.84) and 1.26 (90 % CI: 0.79, 2.01), respectively, for
gemcitabine, and ratios of 0.95 (90 % CI: 0.90, 1.00) and
1.21 (90 % CI: 1.08, 1.36), respectively, for dFdU. This
overall assessment is limited by both pharmacokinetic
variability and small sample size.
Clinical activity
One partial objective response was initially reported on
Day 42 (end of Cycle 2) and sustained through the last
Table 4 Summary of concentrations of pazopanib, gemcitabine, and dFdU from sparse sampling in the dose-escalation phase
Dose cohort Cycle day Nominal time N Median concentration (range)
Pazopanib concentrations (lg/mL)
Paz400/Gem1000 C1D1 3.5 h 6 22.5 (6.5–42.8)
C1D8 Pre-dose 6 22.3 (10.4–37.1)
C2D1 Pre-dose 6 21.6 (1.0–30.8)
Paz800/Gem1000 C1D1 3.5 h 3 51.0 (36.0–52.1)
C1D8 Pre-dose 3 24.9 (11.9–52.4)
C2D1 Pre-dose 3 22.9 (10.9–80.3)
Paz800/Gem1250 C1D1 3.5 h 7 20.7 (7.6–43.3)
C1D8 Pre-dose 6 23.9 (8.6–37.6)
C2D1 Pre-dose 4 19.1 (7.4–25.1)
Gemcitabine concentrations (ng/mL)a
Paz400/Gem1000 C1D1 0.5 h 6 10,532 (1,318–11,647)
C1D8 0.5 h 6 9,691 (994–25,529)
Paz800/Gem1000 C1D1 0.5 h 3 10,820 (9,375–13,881)
C1D8 0.5 h 3 18,936 (7,913–22,638)
Paz800/Gem1250 C1D1 0.5 h 7 17,854 (8,130–22,541)
C1D8 0.5 h 6 16,006 (5,274–21,032)
dFdU concentrations (ng/mL)
Paz400/Gem1000 C1D1 0.5 h 6 29,672 (15,654–54,539)
C1D8 Pre-dose 6 301 (0–997)
C1D8 0.5 h 6 31,005 (17,927–38,586)
Paz800/Gem1000 C1D1 0.5 h 3 41,032 (22,844–43,207)
C1D8 Pre-dose 3 743 (686–1,745)
C1D8 0.5 h 3 40,789 (24,614–41,044)
Paz800/Gem1250 C1D1 0.5 h 7 34,175 (21,999–45,346)
C1D8 Pre-dose 6 889 (0–1,678)
C1D8 0.5 h 6 35,378 (27,767–49,545)
C cycle, D day, dFdU 20,20-difluorodeoxyuridine, Gem gemcitabine, h hour, Paz pazopanib
a C1D8 pre-dose concentrations for gemcitabine were all less than lower limit of quantitation (50 ng/mL)
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Fig. 1 Median pazopanib,
gemcitabine, and dFdU
concentration–time profiles
from patients in the cohort-
expansion phase: gemcitabine
(1,250 mg/m2 by 30-min
infusion) was administered
alone on Cycle 1 Day 1 (C1D1)
and in combination with oral
pazopanib (800 mg) on Cycle 2
Day 1 (C2D1); pazopanib was
administered once daily
beginning on C1D2, and
gemcitabine was administered
on Days 1 and 8 of the 21-day
cycle
Table 5 Summary of pharmacokinetic parameter estimates and statistical results for pazopanib, gemcitabine, and dFdU from the cohort-
expansion phase
PK Parameter Pazopanib Gemcitabine dFdU
C2D1a C1D1a C2D1a GLM Ratio
(90 % CI)b




























AUC(0–24) (h*lg/mL) 1,340 (5)
680–1,777
– – – – – –

































Cmin (lg/mL) 37.5 (5)
21.5–56.8
– – – – – –
AUC(0-24) area under the concentration–time curve 0–24 h, AUC(0–?) AUC extrapolated to infinity, C cycle, CI confidence interval, CL
clearance, Cmax maximum concentration, Cmin minimum concentration, D day, dFdU 2
0,20-difluorodeoxyuridine, GLM geometric least squares
mean, h hour, PK pharmacokinetic, Tmax time of Cmax, t1/2 elimination half-life
a Values denote median (n) and range
b Values denote GLM ratio of (C2D1/C1D1) and 90 % CI from analysis of variance
c Units for Cmax are lg/mL for pazopanib and ng/mL for gemcitabine and dFdU
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assessment on Day 327 in a female patient with melanoma
in the Paz800/Gem1250 cohort. Fourteen patients had
stable disease at 1 or more disease assessment time points;
three of these patients had stable disease for at least 12
cycles (cholangiocarcinoma, 17 cycles; melanoma, 14
cycles; and colorectal cancer, 12 cycles).
Discussion
This study demonstrated that pazopanib and gemcitabine
can be safely administered at doses similar to those given
as monotherapy. The most common AEs experienced by
patients receiving the combination of pazopanib and
gemcitabine were consistent with the known safety profile
of each agent individually. The most frequently reported
treatment-related AEs were fatigue, neutropenia, nausea,
decreased appetite, and thrombocytopenia.
No apparent pharmacokinetic interaction between paz-
opanib and gemcitabine was observed. However, the
assessment was limited by extensive interpatient variability
and small sample size. Although this study did not have a
period of pazopanib monotherapy without gemcitabine, the
pazopanib pharmacokinetic parameters were similar to
historical results from pazopanib 800 mg monotherapy
[19], suggesting no apparent effect of gemcitabine on
pazopanib pharmacokinetics. The pharmacokinetic
parameters for gemcitabine and dFdU from both gemcita-
bine alone (Cycle 1 Day 1) and in combination with paz-
opanib (Cycle 2 Day 1) were also similar to historical
estimates [20, 21].
Preliminary clinical activity was characterized by one
patient with a partial objective response and 14 patients
with stable disease, including three patients in whom the
duration of stable disease ranged from 12 to 17 treatment
cycles (21-day cycles).
In summary, therapeutic doses associated with efficacy
of both pazopanib and gemcitabine monotherapy were
achieved. There was no apparent pharmacokinetic inter-
action at the highest dose level tested (Paz800/Gem1250),
although interindividual variability and small sample size
limit the robustness of this inference. The combination of
pazopanib and gemcitabine was generally well tolerated,
and Phase 2 studies of this combination are warranted.
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